Advertisement

Topics

Latest "Debiopharm Group" News Stories

02:07 EST 18th December 2017 | BioPortfolio

Here are the most relevant search results for "Debiopharm Group" found in our extensive news archives from over 250 global news sources.

More Information about Debiopharm Group on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Debiopharm Group for you to read. Along with our medical data and news we also list Debiopharm Group Clinical Trials, which are updated daily. BioPortfolio also has a large database of Debiopharm Group Companies for you to search.

Showing "Debiopharm Group" News Articles 1–25 of 9,800+

Extremely Relevant

Lancement de « patients.debiopharm.com », un site internet sur les essais cliniques de ...

Debiopharm International SA (Debiopharm -  www.debiopharm.com), membre de Debiopharm Group ™, société biopharmaceutique mondiale basée en Suisse, a annoncé aujourd'hui le lancement d'un nouveau Read more...


Debiopharm International SA Launches Clinical Trials Website: patients.debiopharm.com

     (Photo: http://mma.prnewswire.com/media/608971/Debiopharm_International_Website.jpg) Debiopharm's main therapeutic areas are oncology and infectious diseases. The company is currently conducting trials in multiple indications like Ovarian cancer, Read more...

Relevant

6,8 M€ pour Hybrigenics et 2,23 M€ pour Debiopharm international

Tous les jours un bref écho des principales infos de la veille avec le remindHIER de BiotechFinances Hybrigenics (FR0004153930- ALHYG), nouveaux médicaments contre les maladies prolifératives, annonce le succès de son augmentation de capital avec maintien du droit préférentiel de souscription des actionnaires (« DPS »). La demande de souscriptions a porté sur un montant global de 8,8 &...


Debiopharm completes enrollment in Phase I/II of Debio 1143 for SCCHN

The And Debiopharm Announce Winners Of The 2017 JCA-Mauvernay Award

  Life Sciences Jobs   ...

Debiopharm Awarded $2.6 Million Grant From CARB-X To Support Development Of Debio 1453 To Fight Drug Resistant Gonorrhea

  Life Sciences Jobs   ...

Arbor Pharma And Debiopharm Announce Commercial Availability Of Triptodur, Triptorelin 6-Month Formulation, For Treatment Of Central Precocious Puberty (CPP)

  Life Sciences Jobs   ...

Debiopharm Group Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 08112017] Prices from USD $250

SummaryDebiopharm Group Debiopharm is a pharmaceutical company that develops biologics and small molecule drug candidates targeted at unmet medical needs. The company provides products portfolio such as eloxatin, elplat, dacotin, dacplat, decapeptyl, neo decapeptyl, trelstar, pamorelin, salvacyl and moapar, among others. It also provides services such as clinical development, manufacturing and qua...

Debiopharm Group Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 26072017] Prices from USD $250

SummaryDebiopharm Group Debiopharm is a developer of biologics and small molecule drug candidates targeted at unmet medical needs. The company's products portfolio includes eloxatin, elplat, dacotin, dacplat, decapeptyl, neo decapeptyl, trelstar, pamorelin, salvacyl and moapar, among others. It also offers services such as clinical development, manufacturing and quality assurance, regulatory servi...

Debiopharm Innovation Fund SA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 08112017] Prices from USD $250

SummaryDebiopharm Innovation Fund SA Debiopharm Diagnostics, formerly Debiopharm Diagnostics SA, a subsidiary of Debiopharm Group, is a patient care investment company that offers drug investments and development stage diagnostics solutions. The company offers investments for drugs on cancer severity and recurrence, omics and clinical big data management, point of care turnkey Dx platforms, bloodb...

PTV News: Jan 8, 2010

Top stories on January 8th, 2010: Huge potential: Vivus obesity drug cuts sleep apnea too Lundbeck investigated by EU over generic claims Second stab: Debiopharm to develop Pfizer failure Cyclacel's changing fortunes Action Shares Risk averse: Why Australian investors are still shy of biotech

Debiopharm Diagnostics SA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 26072017] Prices from USD $250

SummaryDebiopharm Diagnostics SA Debiopharm Diagnostics, formerly Debioinnovation S.A. is a subsidiary of Debiopharm Group, a biopharmaceutical company. The company's products include pharmaceutical instruments and cartridges, costeffective and rapid molecular devices, lifesaving detection devices, medical devices, and pharmaceutical devices. It offers services such as simple and rapid molecular d...

Debiopharm International SA Medical Equipment Deals and Alliances Profile [Report Updated: 12072017] Prices from USD $250

SummaryDebiopharm International SA Debiopharm, a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug development solutions. It evaluates, searches, and inlicenses promising drug candidates for development. Debiopharm's products includes decapeptyl, eloxatin, pamorelin, trelstar, moapar and salvacyl among o...

Debiopharm International SA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 26072017] Prices from USD $250

SummaryDebiopharm International SA Debiopharm, a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug development solutions. It evaluates, searches, and inlicenses promising drug candidates for development. Debiopharm's products includes decapeptyl, eloxatin, pamorelin, trelstar, moapar and salvacyl among o...

Triptodur Becomes Commercially Available For Treatment Of Central Precocious Puberty

NewsArbor Pharmaceuticals, LLC and Debiopharm International SA announce commercial availability of Triptodur, triptorelin 6-month formulation, for treatment of central precocious puberty (CPP).

Probably Relevant

Huobi Group and SBI Group reached a strategic partnership agreement to jointly develop Global ...

Huobi Group was founded in 2013. After four years of steady operation, the Group has become a leading global digital asset financial service provider in Read more...

Maricann Group Inc.: Maricann Group expandiert in -2-

DJ Maricann Group Inc.: Maricann Group expandiert in den Spirituosenmarkt - genau wie Canopy Growth! Dow Jones hat von EQS/DGAP eine Zahlung für die Verbreitung dieser Pressemitteilung über sein N...

Maricann Group Inc.: Maricann Group - Lizenz zur -2-

DJ Maricann Group Inc.: Maricann Group - Lizenz zur Produktion von Cannabis Kapseln! - Übernahmeangebote bei Konkurrenten! Dow Jones hat von EQS/DGAP eine Zahlung für die Verbreitung dieser Presse...

Maricann Group Inc.: Maricann Group - Effizienz -2-

DJ Maricann Group Inc.: Maricann Group - Effizienz durch Automatisierung um bis zu 75 % erhöht! Dow Jones hat von EQS/DGAP eine Zahlung für die Verbreitung dieser Pressemitteilung über sein Netzwe...

ARBOR PHARMACEUTICALS, LLC AND DEBIOPHARM INTERNATIONAL SA ANNOUNCE COMMERCIAL AVAILABILITY OF TRIPT

ARBOR PHARMACEUTICALS, LLC AND DEBIOPHARM INTERNATIONAL SA ANNOUNCE COMMERCIAL AVAILABILITY OF TRIPTODUR™, TRIPTORELIN 6-MONTH FORMULATION, FOR TREATMENT OF CENTRAL PRECOCIOUS PUBERTY (CPP) Triptodur™, (triptorelin) extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty associated with CPP via a once every six-month intramuscular (IM) injectio...

In the blink of an eye: People perceive sex ratio and threat of group in less than a second

New research shows people perceive the sex ratio of a group, and decide if the group is threatening or not, in half a second. The perceptions of the number of men in the group are accurate, according to the research.

Maricann Group Inc. Enters Into Letter of Intent with McKesson Canada Retail Banner Group / Maricann and McKesson Canada Retail Banner Group have agreed to a primary collaborative partnership to provide education and awareness for medicinal cannabis to p

TORONTO, ONTARIO -- (Marketwired) -- 08/01/17 -- Maricann Group Inc. (MARI, Maricann or the "Company") and McKesson Canada Retail Banner Group (MCK "McKesson"), consisting of independent pharmacie...

/NOTICE TO DISREGARD - Maricann Group Inc.

TORONTO, ONTARIO -- (Marketwired) -- 08/02/17 -- We are advised by Maricann Group Inc. (CSE: MARI)(CSE: MARI.CN)(CNSX: MARI) that journalists and other readers should disregard the news release, "Maricann Group Enters Into Letter of Intent with McKesson Canada Retail Banner Group", issued Tuesday, August 01, 2017, over Marketwired.

Surprising monkey study: Bad times do not cause group members to change behavior

(University of Southern Denmark) Researchers have observed an unexpected behavioral pattern in monkeys in Puerto Rico. As the population density in the group rises, the group as a whole produces fewer babies -- this is no surprise. But, to the surprise of researchers, it turned out that the group's individual members did not change behavior. How does this add up?

EDB Group: Carola Schropp on the Role of EBD Group conferences in partnering and deal making

In this episode of PharmaTelevsion News Review, Fintan Walton discusses the recent BioPharm America conference in Boston with Carola Schropp from the EBD Group. • Role of EBD Group conferences in partnering and deal making • The impact of conferences in actual deal making • EBD Group 's perspective: The state and changes in pharma and biotech industry • EBD Group 's perspective on futu...


Quick Search
Advertisement
 

News Quicklinks